teaser
Sanofi-Aventis has received a boost from the French agency whichdeals with reimbursement after it gave a favourable recommendation forthe use of the firm’s obesity and diabetes drug rimonabant (Acomplia).
The Transparency Committee (Commission de la Transparence) hasrecommended that the government reimburse rimonabant for obese patientswho are unable to control their type 2 diabetes with a monotherapy ofmetformin or a sulfonylurea, and who have an HBA1c level of between6.5% and 10%. The committee has also suggested that the treatmentshould be combined with diet and physical activity.
